Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Curaleaf Holdings Inc T.CURA

Alternate Symbol(s):  CURLF

Curaleaf Holdings, Inc. is an international provider of consumer cannabis products. The Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide selection and accessibility across the medical and adult use markets. It operates in approximately 17 states and owns and operates 147 dispensaries and 21 cultivation sites with a focus on states, including Arizona, Florida, Illinois, Massachusetts, New Jersey, New York and Pennsylvania. It cultivates, processes, markets and/or dispenses a range of permitted cannabis products across its operating markets, including flower and pre-rolls, dry-herb vaporizer cartridges, concentrates for vaporizing such as pre-filled vaporizer cartridges and disposable vaporizer pens, concentrates for dabbing, such as mints, topical balms and lotions, tinctures, lozenges, capsules and edibles. Through Curaleaf International Holdings Limited, it has a supply and distribution network throughout the European market.


TSX:CURA - Post by User

Post by blackspade799on Oct 23, 2024 2:37pm
81 Views
Post# 36278977

Medical cannabis could save NHS £4 billion each year

Medical cannabis could save NHS £4 billion each year

Prescribing medical cannabis for chronic pain could save the NHS almost £4 billion annually, according to new research.

The findings come from an independent economic analysis of medical cannabis for the treatment of chronic pain, undertaken by York Health-Economics Consortium at the University of York. 

Researchers found that when a patient was prescribed medical cannabis for chronic pain, instead of alternative treatments, this saved the NHS £729 each year, as well as improving health outcomes.

It is estimated that if this were available as a treatment to the 5.45 million people with moderately or severely disabling chronic pain, it would equate to a £3.97 billion annual saving to the NHS.

https://cannabishealthnews.co.uk/2024/10/23/economic-analysis-finds-medical-cannabis-could-save-nhs-4-billion-each-year/

<< Previous
Bullboard Posts
Next >>